Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Medpace Holdings Inc (MEDP) Price & Performance

Duolingo IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Medpace Holdings Inc — how do they compare? Duolingo Inc trades at $132.14 (market cap $6.34B), while Medpace Holdings Inc trades at $599.14 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.7× Duolingo Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.

DUOLMEDP
Market Cap
$6.34B$16.90B
Sector
TechnologyTechnology
52-Week High
$369.19$620.59
52-Week Low
$90.03$393.42
Enterprise Value
$5.11B$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo trades at $131.94, down 3.83% amid mixed signals. The stock shows strong fundamentals with revenue growing from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $129. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.

The outlook remains cautiously optimistic with 30% analyst buy ratings but significant execution risk. Growth investments pressure near-term margins while user engagement strengthens. Key risks include monetization challenges and competitive threats in the edtech space. The consensus price target of $121 suggests limited upside from current levels.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP